Takeda Pharmaceutical (NYSE:TAK) Downgraded by Zacks Research to "Strong Sell"

Key Points

• Takeda Pharmaceutical has been downgraded by Zacks Research from a "hold" rating to a "strong sell" rating, signaling a negative outlook for the company's stock.
• The company reported EPS of $0.52 for the last quarter, exceeding analyst expectations, but its revenue of $7.45 billion fell short of the projected $7.96 billion.
• Despite the downgrade, Takeda's stock saw a 1.3% increase in trading on the day of the report, opening at $15.5030.

Takeda Pharmaceutical (NYSE:TAK - Get Free Report) was downgraded by analysts at Zacks Research from a "hold" rating to a "strong sell" rating in a research note issued to investors on Thursday,Zacks.com reports.

Takeda Pharmaceutical Stock Performance

Shares of NYSE:TAK traded down $0.02 during trading on Thursday, hitting $14.87. 1,897,856 shares of the company were exchanged, compared to its average volume of 2,555,373. Takeda Pharmaceutical has a 52-week low of $12.80 and a 52-week high of $15.56. The stock has a 50 day moving average of $14.80 and a 200 day moving average of $14.71. The company has a debt-to-equity ratio of 0.60, a current ratio of 1.16 and a quick ratio of 0.59. The company has a market cap of $47.30 billion, a PE ratio of 49.55 and a beta of 0.22.

Takeda Pharmaceutical (NYSE:TAK - Get Free Report) last released its quarterly earnings data on Wednesday, July 30th. The company reported $0.52 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.47 by $0.05. Takeda Pharmaceutical had a return on equity of 10.50% and a net margin of 3.20%.The company had revenue of $7.45 billion for the quarter, compared to analyst estimates of $7.96 billion. Takeda Pharmaceutical has set its FY 2025 guidance at 3.360-3.360 EPS. As a group, equities research analysts predict that Takeda Pharmaceutical will post 1.64 EPS for the current year.

Institutional Trading of Takeda Pharmaceutical

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. JPMorgan Chase & Co. boosted its holdings in Takeda Pharmaceutical by 94.5% in the 4th quarter. JPMorgan Chase & Co. now owns 83,826 shares of the company's stock valued at $1,110,000 after purchasing an additional 40,721 shares during the period. Raymond James Financial Inc. bought a new stake in Takeda Pharmaceutical during the fourth quarter valued at $1,447,000. Marshall Wace LLP purchased a new position in Takeda Pharmaceutical during the fourth quarter worth about $1,010,000. Dimensional Fund Advisors LP increased its stake in Takeda Pharmaceutical by 60.0% in the 4th quarter. Dimensional Fund Advisors LP now owns 181,929 shares of the company's stock worth $2,409,000 after acquiring an additional 68,200 shares during the last quarter. Finally, Tower Research Capital LLC TRC raised its holdings in shares of Takeda Pharmaceutical by 413.2% in the 4th quarter. Tower Research Capital LLC TRC now owns 20,898 shares of the company's stock valued at $277,000 after acquiring an additional 16,826 shares in the last quarter. Institutional investors own 9.17% of the company's stock.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.